China Resources Boya Bio-pharmaceutical Group Co., Ltd. (300294.SZ) engages in the research, development, production, and sale of blood products and related pharmaceuticals in China. The company offers a comprehensive portfolio of blood products including human blood albumin, human immunoglobulins such as intravenous human immunoglobulin and hepatitis B human immunoglobulin, rabies immunoglobulin, coagulation factors like human fibrinogen, and freeze-dried intravenous human immunoglobulin; biochemical drugs such as bone polypeptide, oxytocin, and heparin sodium; chemical medicines including diabetes treatments like metformin hydrochloride enteric-coated tablets, glimepiride tablets, pioglitazone hydrochloride dispersible tablets, and calcium dobesilate capsules, as well as anti-infective, cardiovascular, and cerebrovascular drugs; and active pharmaceutical ingredients. Founded in 1993 and headquartered in Fuzhou, Jiangxi Province, the company operates primarily in China through production bases, single plasma collection stations, and a network of member enterprises, serving medical and health markets as a key platform under China Resources Health Division. Recent developments include its restructuring and full integration into China Resources Pharmaceutical Group, solidifying its position in the biopharmaceutical sector; board appointments approved in 2025 to strengthen governance; and involvement in provincial key R&D projects in Jiangxi, alongside operational enhancements such as updates to product information disclosures for human albumin injections and procurement for plasma stations.